LU92301I2 - "Nepafenac - suspension ophtalmique" - Google Patents

"Nepafenac - suspension ophtalmique"

Info

Publication number
LU92301I2
LU92301I2 LU92301C LU92301C LU92301I2 LU 92301 I2 LU92301 I2 LU 92301I2 LU 92301 C LU92301 C LU 92301C LU 92301 C LU92301 C LU 92301C LU 92301 I2 LU92301 I2 LU 92301I2
Authority
LU
Luxembourg
Prior art keywords
nepafenac
ophthalmic suspension
compositions
eye
ophthalmic
Prior art date
Application number
LU92301C
Other languages
English (en)
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21988983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92301(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of LU92301I2 publication Critical patent/LU92301I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU92301C 1997-07-29 2013-10-31 "Nepafenac - suspension ophtalmique" LU92301I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5413297P 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
LU92301I2 true LU92301I2 (fr) 2013-12-31

Family

ID=21988983

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92301C LU92301I2 (fr) 1997-07-29 2013-10-31 "Nepafenac - suspension ophtalmique"

Country Status (19)

Country Link
US (6) US6403609B1 (fr)
EP (2) EP0999825B1 (fr)
JP (2) JP3979783B2 (fr)
KR (1) KR100507984B1 (fr)
CN (3) CN100408100C (fr)
AR (1) AR013272A1 (fr)
AT (2) ATE391492T1 (fr)
AU (1) AU737442B2 (fr)
BR (1) BR9811574B1 (fr)
CA (1) CA2296080C (fr)
CY (2) CY1110365T1 (fr)
DE (2) DE69818675T2 (fr)
DK (2) DK0999825T3 (fr)
ES (2) ES2206965T3 (fr)
LU (1) LU92301I2 (fr)
PT (2) PT1348427E (fr)
TW (2) TWI233801B (fr)
WO (1) WO1999006023A1 (fr)
ZA (1) ZA986533B (fr)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
AU725552B2 (en) 1997-07-29 2000-10-12 Alcon Laboratories, Inc. Conditioning solutions for hard contact lens care
ATE391492T1 (de) * 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
US7169755B2 (en) 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US20090258955A1 (en) * 2000-12-20 2009-10-15 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
DE60141477D1 (de) * 2000-12-20 2010-04-15 Alcon Inc Intraoculare irrigationslösung mit verbesserten fliesseigenschaften
US6878694B2 (en) 2000-12-20 2005-04-12 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
AU2002232437A1 (en) 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic lubricating solution adapted for use in lasik surgery
CA2451334C (fr) * 2001-06-22 2008-09-09 Jeffrey C. Dawson Fluides de fracturation et leurs procedes de preparation et d'utilisation
FR2832223B1 (fr) 2001-11-15 2005-01-14 Cit Alcatel Composant monolithique electro-optique multisections
EP1474109B1 (fr) * 2001-12-21 2010-08-25 Alcon, Inc. Utilisation de nanoparticules synthetiques inorganiques comme vecteurs de medicaments ophtalmiques
EP1455804A4 (fr) * 2001-12-21 2005-01-05 Alcon Inc Utilisation de nanoparticules en tant qu'excipients pour biocides dans des compositions ophtalmiques
EP1471925A2 (fr) * 2001-12-21 2004-11-03 Alcon, Inc. Utilisation de nanoparticules inorganiques dans le but de modifier la viscosite et d'autres proprietes physiques de compositions pharmaceutiques ophtalmiques et otiques
WO2003072081A1 (fr) * 2002-02-22 2003-09-04 Pharmacia Corporation Formulation ophtalmique contenant un systeme de gomme
US7259192B2 (en) 2002-06-25 2007-08-21 Rhodia, Inc. Molecular weight reduction of polysaccharides by electron beams
ATE529447T1 (de) * 2002-06-25 2011-11-15 Rhodia Propfpolymerisation von guar durch elektronenstrahlen
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE528003T1 (de) 2002-07-31 2011-10-15 Senju Pharma Co Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US7914803B2 (en) 2003-06-13 2011-03-29 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
CA2839847C (fr) * 2003-06-13 2016-03-15 Masood A. Chowhan Compositions ophtalmologiques contenant une association synergique de deux polymeres
AU2012205283B2 (en) * 2003-06-13 2014-08-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
CA2545947A1 (fr) * 2003-12-11 2005-07-07 Alcon, Inc. Compositions ophtalmologiques contenant un systeme gelifiant a base de polysaccharide/borate
US20050129770A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Ophthalmic compositions containing a PVA/borate gelling system
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP1720579A1 (fr) * 2004-02-17 2006-11-15 Wheli Inter AG Galactomannane et/ou glucomannane pour augmenter la disponibilite biologique d'agents actifs
JP4881159B2 (ja) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ チアゾール誘導体を含む水性組成物
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
KR100665299B1 (ko) * 2004-06-10 2007-01-04 서울반도체 주식회사 발광물질
ATE514412T1 (de) * 2004-08-03 2011-07-15 Rhodia Polysaccharid-pfropfcopolymere und ihre verwendung bei der haarpflege
JP4771044B2 (ja) * 2004-09-15 2011-09-14 大正製薬株式会社 粘膜適用液剤
EP3103477A1 (fr) * 2004-09-17 2016-12-14 Durect Corporation Composition anesthésique locale prolongée contenant du saib
US20070059274A1 (en) * 2004-12-01 2007-03-15 Bahram Asgharian Ophthalmic compositions containing a PVA/borate gelling system
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070048338A1 (en) * 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070259021A1 (en) * 2006-05-01 2007-11-08 Friedlaender Mitchell H Compositions, Methods, and Kits for Treating Dry Eye
WO2008036855A2 (fr) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Compositions pharmaceutiques aqueuses auto-conservées
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
CN101522171A (zh) * 2006-09-28 2009-09-02 爱尔康研究有限公司 自身防腐的水性药物组合物
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
US9157063B2 (en) * 2007-01-16 2015-10-13 Texas Tech University System Method and apparatus for gender selection based on pH
MX2009007774A (es) * 2007-02-09 2009-07-31 Alcon Inc Composiciones oftalmicas que contienen una combinacion sinergistica de tres polimeros.
US8080418B2 (en) * 2007-03-09 2011-12-20 Corning Incorporated Method of making a three dimensional cell culture matrix
WO2008112163A1 (fr) * 2007-03-09 2008-09-18 Corning Incorporated Revêtements à base de gomme pour culture cellulaire, procédés de fabrication et procédés d'utilisation
MX2009012645A (es) * 2007-05-24 2010-03-08 Aciex Therapeutics Inc Formulaciones y metodos para tratar el ojo seco.
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
EP3326621A1 (fr) * 2007-12-06 2018-05-30 Durect Corporation Formes orales de dosage pharmaceutique
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
BRPI0909738A2 (pt) * 2008-03-17 2015-10-06 Alcon Res Ltd composições farmacêuticas aquosas contendo complexos de boratopoliol
NZ589323A (en) * 2008-04-26 2012-04-27 Alcon Res Ltd Polymeric artificial tear system
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MX2011007714A (es) * 2009-02-05 2011-12-06 Alcon Res Ltd Proceso para purificar goma guar.
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
TWI547522B (zh) * 2009-07-07 2016-09-01 愛爾康研究有限公司 環氧乙烷環氧丁烷嵌段共聚物組成物
PL2506831T3 (pl) * 2009-12-03 2014-05-30 Alcon Res Ltd Zawiesiny zawierające nanocząsteczkowe polimery karbowinylowe
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
KR20130060228A (ko) 2010-05-05 2013-06-07 알콘 리서치, 리미티드 안정화된 안과용 갈락토만난 제제
CN102946855B (zh) * 2010-06-23 2016-01-06 爱尔康研究有限公司 含有妥布霉素和地塞米松的局部用眼科混悬剂
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP3045163A1 (fr) 2011-04-22 2016-07-20 Alcon Research, Ltd. Composition ophtalmique comprenant un système d'amélioration de la viscosité constitué de deux agents d'amélioration de la viscosité différents
CN104039307A (zh) 2011-04-22 2014-09-10 爱尔康研究有限公司 具有包含两种不同粘度增强剂的粘度增强体系的眼用组合物
HUE047642T2 (hu) 2011-11-21 2020-05-28 Calithera Biosciences Inc A glutamináz heterociklusos gátlói
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
UA113434C2 (uk) 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
CN102860949B (zh) * 2012-08-31 2014-07-02 马应龙药业集团股份有限公司 眼部抗皱护肤品及其制备方法
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP3013790A1 (fr) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Procédé pour la préparation de népafénac
US10350161B2 (en) 2013-10-15 2019-07-16 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
FR3000391B3 (fr) 2013-11-12 2015-02-20 Pharmathen Sa Compositions pharmaceutiques sans conservateur pour administration ophtalmique
CN103572651B (zh) * 2013-11-25 2016-05-04 齐鲁工业大学 一种改性塔拉胶及其制备方法与应用
WO2015142853A1 (fr) * 2014-03-17 2015-09-24 Encompass Development, Inc. Formulations oculaires
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
CA2957225A1 (fr) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Formes cristallines d'inhibiteurs de glutaminase
EP3180332B1 (fr) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines en tant que modulateurs des récepteurs de l'orexine
US20170368192A1 (en) 2014-10-13 2017-12-28 Symic Ip, Llc Luminal vessel coating for arteriovenous fistula
WO2016061145A1 (fr) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Protéoglycanes synthétiques pour empêcher l'adhérence tissulaire
WO2016065083A1 (fr) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycanes comprenant des peptides se fixant au collagène pour le traitement d'une lésion gastro-œsophagienne
MX384444B (es) 2015-03-10 2025-03-14 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
AU2016301235B2 (en) 2015-08-03 2020-08-20 Championx Usa Inc. Compositions and methods for delayed crosslinking in hydraulic fracturing fluids
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
WO2017066349A1 (fr) 2015-10-13 2017-04-20 Symic Ip, Llc Bioconjugué se liant à la ve-cadhérine
US11576973B2 (en) 2015-10-25 2023-02-14 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
US10745435B2 (en) 2015-11-16 2020-08-18 Cerecor, Inc. Nucleic acid prodrugs
JP6703408B2 (ja) * 2016-01-30 2020-06-03 国立大学法人 筑波大学 ポリイオンコンプレックスを有効成分とするドライアイ処置用組成物
KR102738491B1 (ko) 2016-02-12 2024-12-03 아스트라제네카 아베 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
US10087363B2 (en) * 2016-03-15 2018-10-02 Baker Hughes, A Ge Company, Llc Using borated galactomannan to enhance swelling of superabsorbents for fracturing applications
US20190134069A1 (en) 2016-04-22 2019-05-09 Viking Therapeutics, Inc. Use of thyroid beta-agonists
WO2017210565A1 (fr) 2016-06-03 2017-12-07 Prisident And Fellows Of Harvard College Composés antifongiques
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
US10550315B2 (en) 2016-07-15 2020-02-04 Ecolab Usa Inc. Compositions and methods for delayed crosslinking in hydraulic fracturing fluids
WO2018039591A1 (fr) 2016-08-25 2018-03-01 California Institute Of Technology Traitement ascaroside de maladies auto-immunes et inflammatoires
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
WO2018049094A1 (fr) 2016-09-09 2018-03-15 The Regents Of The University Of California Ligands du récepteur des oestrogènes, compositions et méthodes associées
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
EP3515449B1 (fr) 2016-09-26 2023-07-12 Dana-Farber Cancer Institute, Inc. Dérivés de quinoline en tant qi'inhibiteurs de la protéine chromobox (cbx) pour le traitement du cancer
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
JP2020511424A (ja) 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害としての縮合複素環式化合物
WO2018154088A1 (fr) 2017-02-24 2018-08-30 Merck Patent Gmbh Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
AU2018242623B2 (en) 2017-03-31 2024-05-02 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
WO2018223032A1 (fr) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Formes cristallines de sel de sbt-20
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
AU2018346331B2 (en) 2017-10-04 2023-08-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor SALL4 and uses thereof
BR112020006669A2 (pt) 2017-10-11 2020-09-24 Aurigene Discovery Technologies Limited formas cristalinas de 1,2,4-oxadiazol 3-substituído
KR20200072479A (ko) 2017-10-19 2020-06-22 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물에 대한 DMPC, DMPG, DMPC/DMPG, LysoPG 및 LysoPC의 보호 효과
KR102697663B1 (ko) 2017-10-31 2024-08-21 쿠리스 인코퍼레이션 혈액학적 장애를 치료하기 위한 화합물 및 조성물
KR20200083503A (ko) 2017-11-03 2020-07-08 오리진 디스커버리 테크놀로지스 리미티드 Tim-3 경로와 pd-1 경로의 이중 저해제
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
RU2020124097A (ru) 2017-12-22 2022-01-24 Медиммьюн Лимитед НИЗКОМОЛЕКУЛЯРНЫЕ МОДУЛЯТОРЫ ДОМЕНА BTB Keap1
TWI884130B (zh) 2018-02-21 2025-05-21 瑞士商愛爾康公司 基於脂質的眼用乳劑
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
MX2020009443A (es) 2018-03-14 2021-01-08 Aurigene Discovery Tech Ltd Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
CA3107750A1 (fr) 2018-07-27 2020-01-30 California Institute Of Technology Inhibiteurs de cdk et leurs utilisations
CN110787126A (zh) * 2018-08-03 2020-02-14 武汉武药科技有限公司 一种盐酸莫西沙星眼用凝胶及其制备方法
KR20210071974A (ko) 2018-09-05 2021-06-16 더 제너럴 하스피탈 코포레이션 사이토카인 방출 증후군을 치료하는 방법
EP3849310A4 (fr) 2018-09-12 2022-07-06 The Board of Regents of the University of Oklahoma Polythérapies anticancéreuses
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
CA3118026A1 (fr) 2018-10-31 2020-05-07 Intocell, Inc. Derives de benzodiazepine heterocycliques fusionnes et leurs utilisations
EP3893945A4 (fr) 2018-12-10 2022-11-30 The General Hospital Corporation Esters cromoglycique et leurs utilisations
EP3911640A4 (fr) 2019-01-18 2022-10-26 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
AU2020234033B2 (en) 2019-03-14 2023-07-13 Astrazeneca Ab Lanabecestat for weight loss
TW202045631A (zh) 2019-03-15 2020-12-16 德商麥克專利有限公司 帶藍色之深黑色效果顏料
EP3978076A4 (fr) 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. Composés d'amide cyclique pour le traitement de la rage et méthode associée
TWI757773B (zh) * 2019-06-28 2022-03-11 瑞士商愛爾康公司 眼用組成物
KR20220034199A (ko) 2019-09-18 2022-03-17 알콘 인코포레이티드 습식-패킹 소프트 하이드로겔 안구 삽입물
CA3157798A1 (fr) 2019-11-12 2021-05-20 Zhongli Gao Heteroarylaminosulfonamides a 6 chainons pour le traitement de maladies et d'etats medies par une activite cftr deficiente
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
CA3164800A1 (fr) 2019-12-16 2021-06-24 Unist(Ulsan National Institute Of Science And Technology) Compose destine a inhiber le facteur d'angiogenese et son utilisation
EP4090353A4 (fr) 2020-01-13 2023-08-09 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.
EP4146205A4 (fr) 2020-05-05 2024-05-29 Nuvalent, Inc. Agents chimiothérapeutiques à base d'éther macrocyclique hétéroaromatique
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
WO2023034946A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
PE20241330A1 (es) 2021-09-03 2024-06-26 Genzyme Corp Compuestos de indol y metodos de uso
WO2023056431A1 (fr) 2021-10-01 2023-04-06 Nuvalent, Inc. Méthodes de traitement d'une tumeur solide à l'aide de composés éther macrocycliques hétéroaromatiques
CA3231813A1 (fr) 2021-10-01 2023-04-06 Sibao CHEN Formes solides, compositions pharmaceutiques et preparation de composes ether macrocycliques heteroaromatiques
CN114191378A (zh) * 2021-11-23 2022-03-18 温州医科大学附属眼视光医院 一种地夸磷索缓释凝胶及其制备方法与应用
WO2023187672A1 (fr) 2022-03-31 2023-10-05 Alcon Inc. Compositions ophtalmiques
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
CN119212705A (zh) 2022-04-07 2024-12-27 纽威伦特公司 使用(19r)-5-氯-3-乙基-16-氟-10,19-二甲基-20-氧杂-3,4,10,11,23-五氮杂戊环[19.3.1.02,6.08,12.013,18]二十五碳-1(24),2(6),4,8,11,13,15,17,21(25),22-癸烯-22-胺治疗实体肿瘤的方法
WO2023224961A1 (fr) 2022-05-16 2023-11-23 Exelixis, Inc. Thérapie anticancéreuse utilisant une association d'un inhibiteur de cdk7 avec un serd oral
KR20250044905A (ko) 2022-08-04 2025-04-01 다이이치 고교 세이야쿠 가부시키가이샤 고리형 펩티드 유도체와 그 제조 방법 및 조성물
WO2024036097A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
WO2024036098A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques
IL319591A (en) 2022-09-30 2025-05-01 Dks Co Ltd Cyclic peptide derivative composition for treating or preventing eye diseases
JPWO2024071371A1 (fr) 2022-09-30 2024-04-04
AU2023364043A1 (en) 2022-10-19 2025-04-10 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN120152726A (zh) 2022-11-04 2025-06-13 第一工业制药株式会社 用于处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
EP4613283A1 (fr) 2022-11-04 2025-09-10 DKS Co. Ltd. Composition de dérivé peptidique cyclique pour le traitement ou la prévention de la douleur neuropathique et/ou de la douleur inflammatoire
EP4705330A1 (fr) 2023-05-05 2026-03-11 The Board of Regents of the University of Oklahoma Variants d'adrénomédulline (am) et d'adrénomédulline 2/intermédine (am2/imd) et procédés d'utilisation
WO2025042868A1 (fr) 2023-08-23 2025-02-27 The Board Of Regents Of The University Of Oklahoma Combinaisons d'hétéroarotinoïdes et d'inhibiteurs glycolytiques destinées à être utilisées en tant que traitements du cancer
WO2025072120A1 (fr) 2023-09-25 2025-04-03 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques
WO2025072117A1 (fr) 2023-09-25 2025-04-03 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
WO2025085360A1 (fr) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Hétéroarotinoïdes et/ou inhibiteurs de cdk4/6 pour le traitement des verrues, des dysplasies induites par le papillomavirus humain (vph), et du cancer chez des individus infectés par le vph
US20250276007A1 (en) 2024-03-04 2025-09-04 Alcon Inc. Carbamoylphenylboronic acid-containing acrylic monomers and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944427A (en) * 1970-04-06 1976-03-16 Itek Corporation Gelable and gelled compositions
US3843782A (en) 1971-07-26 1974-10-22 Flow Pharma Inc Eye solution and method of using same
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4436730A (en) 1979-06-25 1984-03-13 Polymer Technology Corporation Ionic opthalmic cellulose polymer solutions
US4624868A (en) * 1979-12-17 1986-11-25 Colgate-Palmolive Company Borated polysaccharide absorbents and absorbent products
US4323467A (en) 1980-11-24 1982-04-06 Syntex (U.S.A.) Inc. Contact lens cleaning, storing and wetting solutions
JPS57186733A (en) 1981-05-13 1982-11-17 Toyo Contact Lens Co Ltd Agent for use in contact lenses
US4362781A (en) * 1981-09-21 1982-12-07 Scott Paper Company Flushable premoistened wiper
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
CA2011423A1 (fr) 1989-03-07 1990-09-07 Peter M. Taylor Composes pharmaceutiques utiles comme vehicules de medicaments et (ou) pansement
US5145590A (en) 1990-01-16 1992-09-08 Bj Services Company Method for improving the high temperature gel stability of borated galactomannans
US5160643A (en) 1990-01-16 1992-11-03 Bj Services Company Method for delaying the gellation of borated galactomannans with a delay additive such as glyoxal
US5082579A (en) * 1990-01-16 1992-01-21 Bj Services Company Method and composition for delaying the gellation of borated galactomannans
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5376693A (en) 1990-08-07 1994-12-27 Mediventures Inc. Thermo-irreversible gel corneal contact lens formed in situ
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5372732A (en) 1992-10-21 1994-12-13 Halliburton Company Delayed release borate crosslinking agent
WO1994010976A1 (fr) 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Systeme d'administration de medicaments ophtalmiques a base de borate/alcool polyvinylique
JPH06345653A (ja) 1993-06-08 1994-12-20 Asahi Chem Ind Co Ltd 点眼液
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
GB9603146D0 (en) 1996-02-15 1996-04-17 Innovative Tech Ltd Hydrogels
JP3989054B2 (ja) 1996-07-29 2007-10-10 株式会社メニコン コンタクトレンズ用洗浄材
JPH10221654A (ja) 1997-02-07 1998-08-21 Seiko Epson Corp コンタクトレンズ用溶液
AU725552B2 (en) * 1997-07-29 2000-10-12 Alcon Laboratories, Inc. Conditioning solutions for hard contact lens care
PT999854E (pt) * 1997-07-29 2003-12-31 Alcon Mfg Ltd Sistemas viscoelasticos comutaveis contendo polimeros de galactomanano e borato
ATE391492T1 (de) * 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
CA2545947A1 (fr) * 2003-12-11 2005-07-07 Alcon, Inc. Compositions ophtalmologiques contenant un systeme gelifiant a base de polysaccharide/borate

Also Published As

Publication number Publication date
CY1110365T1 (el) 2015-04-29
CN1544092A (zh) 2004-11-10
DE69818675T2 (de) 2004-07-29
EP1348427A1 (fr) 2003-10-01
CY2013040I1 (el) 2015-11-04
AU737442B2 (en) 2001-08-16
CA2296080C (fr) 2005-02-01
WO1999006023A1 (fr) 1999-02-11
ES2302881T3 (es) 2008-08-01
CN1762381A (zh) 2006-04-26
US20070098677A1 (en) 2007-05-03
DE69839355T2 (de) 2009-06-04
PT1348427E (pt) 2008-05-26
AR013272A1 (es) 2000-12-13
TW577751B (en) 2004-03-01
JP3979783B2 (ja) 2007-09-19
CN100408100C (zh) 2008-08-06
DK1348427T3 (da) 2008-06-30
ZA986533B (en) 1999-02-05
ATE250923T1 (de) 2003-10-15
CY2013040I2 (el) 2015-11-04
KR100507984B1 (ko) 2005-08-17
TWI233801B (en) 2005-06-11
EP0999825B1 (fr) 2003-10-01
US6838449B2 (en) 2005-01-04
US6403609B1 (en) 2002-06-11
DE69839355D1 (de) 2008-05-21
JP4673339B2 (ja) 2011-04-20
CN1302201A (zh) 2001-07-04
US20030206970A1 (en) 2003-11-06
US20020183280A1 (en) 2002-12-05
JP2007197461A (ja) 2007-08-09
DE69818675D1 (de) 2003-11-06
US6486138B1 (en) 2002-11-26
ATE391492T1 (de) 2008-04-15
AU8570598A (en) 1999-02-22
US7169767B2 (en) 2007-01-30
HK1055392A1 (en) 2004-01-09
JP2003528797A (ja) 2003-09-30
BR9811574A (pt) 2000-08-29
HK1026618A1 (en) 2000-12-22
PT999825E (pt) 2004-02-27
CA2296080A1 (fr) 1999-02-11
DK0999825T3 (da) 2004-02-09
US6583124B2 (en) 2003-06-24
CN1762381B (zh) 2012-07-11
EP1348427B1 (fr) 2008-04-09
EP0999825A1 (fr) 2000-05-17
CN1229110C (zh) 2005-11-30
BR9811574B1 (pt) 2010-11-30
ES2206965T3 (es) 2004-05-16
US20050075313A1 (en) 2005-04-07
KR20010022286A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
LU92301I2 (fr) "Nepafenac - suspension ophtalmique"
AU6772590A (en) Hair treatment composition
NO975331D0 (no) Anvendelse av R-enantiomer av N-propargyl-1-aminoindan salter og sammensetninger derav
CA2154950A1 (fr) Nouvelles composition et methode de fracturation
FR2719769B1 (fr) Composition cosmétique ou dermatologique sous forme d'huile gélifiée contenant un mélange d'acide hydroxy-12 stéarique ou d'un dialkylamide de l'acide N-lauroylglutamique et d'un copolymère styrène/alcadiène hydrogéné.
FI970489L (fi) Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät doksepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
DE3581768D1 (de) Tensidepraeparate.
DE69526369D1 (de) Entzündungshemmende augentropfen
MA22352A1 (fr) Compositions de type gel ayant une regulation perfectionnee de l'huile
DE69325493D1 (de) Künstliche Speichelzusammensetzungen
ATE240094T1 (de) Ophthalmische zusammensetzungen in form wässriger gele
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
YU48341B (sh) Preparat herbicida
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
BR9303862A (pt) Mesofase esmetica preparada "in vitro" e composicao cosmetica
NO974551L (no) Bruk av sulbutiamin for å fremskaffe farmasöytiske sammensetninger nyttige i behandling av visse psykomotoriske- og psyko-intellektuelle sykdommer
EP0824453A4 (fr) Nouvelles utilisations d'heptafluoropropane
FR2763793B1 (fr) Suspension colloidale de glyphosate, l'un de ses procedes de preparation et composition phytotoxique en contenant
AUPM656494A0 (en) Organism's light computer & games of triangles
FR2743494B1 (fr) Composition aqueuse dentaire a base d'un melange de gomme xanthane et de gomme de guar comme agent epaississant
AU123610S (en) Range hood adaptor
YU84491A (sh) Skrobni hidrolizati
IT9020696A1 (it) Varieta' di pinus nigra nano
UA355S (uk) Головний убір жіночий хутровий